Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.69 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.61 |
| ▸ | SCN7A | Q01118 | 5/20 | 0.61 |
| ▸ | SCN2B | O60939 | 1/20 | 0.59 |
| ▸ | SCN1A | P35498 | 1/20 | 0.59 |
| ▸ | SCN4A | P35499 | 1/20 | 0.59 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.59 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.59 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18571050 | 1.00 | SCN9A (0.69) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL21800824 | 0.98 | SCN9A (0.69) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL18571118 | 0.98 | SCN9A (0.69) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL21800825 | 0.98 | SCN9A (0.69) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL18570781 | 0.97 | SCN9A (0.73) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL18571116 | 0.89 | SCN9A (0.66) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL23861692 | 0.89 | SCN9A (0.68) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL18571441 | 0.88 | SCN9A (0.63) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL18570785 | 0.88 | SCN9A (0.74) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL19075676 | 0.87 | SCN9A (0.66) | SCN9ASCN5ASCN7ASCN2BSCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| WO-2017035271-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | RDX, C3AR1, LPXN | SCN9A 1789/4885SCN5A 1100/4885SCN7A 1281/4885 |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, RDX, MC2R | SCN9A 2486/4885SCN5A 1051/4885SCN7A 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.